AC ImmuneACIU +4.70%26 FCF Yield % is -32.74 as of Jun. 27, 2026. GuruFocus rates ACIU with a GF Score™ of 26/100 and a GF Value™ of $0.75 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,418 Biotechnology companies, AC Immune ranks worse than 77.36% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
AC Immune FCF Yield % Related Terms
AC Immune FCF Yield % Historical Data
* Premium members only.
The historical data trend for AC Immune's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AC Immune's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AC Immune FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AC Immune's FCF Yield % distribution charts can be found below:
* The bar in red indicates where AC Immune's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AC Immune (ACIU) has a FCF Yield % of -32.74 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on AC Immune and its competitors. According to the industry distribution chart, AC Immune ranks #1097 out of 1418 companies in the Biotechnology industry, placing it in the top 77.4%.
Is AC Immune's FCF Yield % too high?
AC Immune's current FCF Yield % is -32.74. Based on the distribution chart, AC Immune ranks #1097 out of 1418 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AC Immune has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AC Immune's FCF Yield % compare to TRDA and MGNX?
According to the Biotechnology industry distribution chart, AC Immune ranks #1097 out of 1418 companies for FCF Yield %. This places AC Immune in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on AC Immune and its competitors. AC Immune's current FCF Yield % is -32.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AC Immune stock overvalued right now?
Based on GuruFocus' analysis, AC Immune (ACIU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.75, compared to a current price of $2.56 — trading 241.3% above its estimated fair value. The current FCF Yield % is -32.74. AC Immune's overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For AC Immune (ACIU), the current FCF Yield % is -32.74 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AC Immune (ACIU) Overvalued in 2026?
Based on GuruFocus' analysis, AC Immune stock appears to be overvalued.
The current stock price of $2.56 is trading 241.3% above its estimated GF Value™ of $0.75.
GuruFocus considers AC Immune to be Significantly Overvalued.
Key valuation signals for ACIU:
FCF Yield %: -32.74
GF Value™: $0.75 vs. price of $2.56 (241.3% above fair value)
No single metric tells the full story. See the ACIU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
26GF Score
Get the complete analysis for ACIU
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACIU has been successfully added to your 
